This article from 2015 does a good job conveying the boom-bust cycle around miracle weight loss drugs pre GLP-1s, and the resulting skepticism with which the medical establishment viewed the category
Even if the solution appears visually normal, a vial that has been stored beyond the sponsor-validated in-use shelf life must be discarded
These modifications include acylation of the peptide backbone with a spacer and a C-18 fatty di-acid chain to lysine at position 26, which mediates strong binding to albumin and potentially results in reduced renal clearance, and an amino-acid substitution in position 8, which results in reduced susceptibility to dipeptidyl peptidase-4 (DPP-4) degradation
This is the future
Individuals taking GLP-1 or GLP-1/GIP drugs experience fatigue, especially during the first few weeks or during the dose escalation phase
Loss of mass in metabolically active organs, such as the liver, is expected as part of healthy weight loss, says Ran Hee Choi, PhD, research instructor in nutrition and integrative physiology at U of U Health and co-first author on the study